BEDFORD, Ohio, Jan. 14 Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., is pleased to announce FDA approval for the addition of 100 mg/50 mL Fluconazole Injection to its existing Fluconazole Injection line. This product is AP rated and is equivalent to DiflucanŽ by Pfizer. Fluconazole Injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated for the prophylaxis of candidiasis.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
"Pharmacists asked, we answered. In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to be the first to offer this unique dosage. Fluconazole Injection 100 mg/50 mL is right-sized for smaller doses, speeding productivity and saving time. This continues to demonstrate our commitment to providing a broad-based portfolio of products," said David Gaugh, Vice President of Bedford Laboratories.
Bedford Laboratories will supply Fluconazole Injection sterile iso-osmotic solution containing 2 mg/mL of fluconazole in glass vials in the following presentations: Vials containing either 100 mg, 200 mg or 400 mg equivalent of fluconazole. In addition, Bedford Laboratories will supply Fluconazole Injection as a sterile iso-osmotic solution containing 2 mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations: 200 mg/100 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400 mg/200 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.
Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.
Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.
About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people. For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.
Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com.
DiflucanŽ is a registered trademark of Pfizer Inc.
SOURCE Bedford Laboratories